Deciphera Pharmaceuticals, Inc. (DCPH)


+0.27 (+2.17%)
Symbol DCPH
Price $12.73
Beta 0.681
Volume Avg. 0.41M
Market Cap 1.003B
Shares () -
52 Week Range 12.41-22.76
1y Target Est -
DCF Unlevered DCPH DCF ->
DCF Levered DCPH LDCF ->
ROE -47.04% Strong Sell
ROA -36.00% Strong Sell
Operating Margin -
Debt / Equity 6.81% Neutral
P/E -5.98 Strong Sell
P/B 2.68 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest DCPH news

Mr. Steven L. Hoerter
Drug Manufacturers—Specialty & Generic
NASDAQ Global Select

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.